Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Capricor Therapeutics (CAPR) over the last 17 years, with Q3 2025 value amounting to -$19.7 million.

  • Capricor Therapeutics' Cash from Operations fell 6911.17% to -$19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$61.0 million, marking a year-over-year decrease of 6590.13%. This contributed to the annual value of -$40.0 million for FY2024, which is 5625.45% down from last year.
  • Per Capricor Therapeutics' latest filing, its Cash from Operations stood at -$19.7 million for Q3 2025, which was down 6911.17% from -$20.1 million recorded in Q2 2025.
  • Capricor Therapeutics' Cash from Operations' 5-year high stood at $24.0 million during Q1 2022, with a 5-year trough of -$20.1 million in Q2 2025.
  • Over the past 5 years, Capricor Therapeutics' median Cash from Operations value was -$6.5 million (recorded in 2022), while the average stood at -$6.5 million.
  • In the last 5 years, Capricor Therapeutics' Cash from Operations skyrocketed by 82225.57% in 2022 and then crashed by 40719.94% in 2025.
  • Capricor Therapeutics' Cash from Operations (Quarter) stood at -$5.6 million in 2021, then dropped by 22.65% to -$6.9 million in 2022, then crashed by 67.98% to -$11.6 million in 2023, then decreased by 27.62% to -$14.8 million in 2024, then plummeted by 33.07% to -$19.7 million in 2025.
  • Its Cash from Operations was -$19.7 million in Q3 2025, compared to -$20.1 million in Q2 2025 and -$6.4 million in Q1 2025.